Next Article in Journal
Improving Outcomes in Patients with CRC: The Role of Patient Reported Outcomes—An ESDO Report
Next Article in Special Issue
Can Integrin Agonists Have Cards to Play against Cancer? A Literature Survey of Small Molecules Integrin Activators
Previous Article in Journal
Chemotherapeutic Drugs: DNA Damage and Repair in Glioblastoma
Previous Article in Special Issue
NG2 Proteoglycan Enhances Brain Tumor Progression by Promoting Beta-1 Integrin Activation in both Cis and Trans Orientations
Article Menu
Issue 6 (June) cover image

Export Article

Open AccessFeature PaperReview
Cancers 2017, 9(6), 56;

RGD-Binding Integrins in Head and Neck Cancers

Radiological Sciences Department, College of Health and Rehabilitation Sciences, Princess Nourah Bint Abdulrahman University, Riyadh 11564, Saudi Arabia
Institute of Cancer Therapeutics, University of Bradford, Bradford BD7 1DP, UK
Author to whom correspondence should be addressed.
Academic Editor: Samuel C. Mok
Received: 21 April 2017 / Revised: 22 May 2017 / Accepted: 23 May 2017 / Published: 26 May 2017
(This article belongs to the Special Issue Integrins in Cancer)
Full-Text   |   PDF [257 KB, uploaded 26 May 2017]


Alterations in integrin expression and function promote tumour growth, invasion, metastasis and neoangiogenesis. Head and neck cancers are highly vascular tumours with a tendency to metastasise. They express a wide range of integrin receptors. Expression of the αv and β1 subunits has been explored relatively extensively and linked to tumour progression and metastasis. Individual receptors αvβ3 and αvβ5 have proved popular targets for diagnostic and therapeutic agents but lesser studied receptors, such as αvβ6, αvβ8, and β1 subfamily members, also show promise. This review presents the current knowledge of integrin expression and function in squamous cell carcinoma of the head and neck (HNSCC), with a particular focus on the arginine-glycine-aspartate (RGD)-binding integrins, in order to highlight the potential of integrins as targets for personalised tumour-specific identification and therapy. View Full-Text
Keywords: integrin αv; β1; β3; β6; arginine-glycine-aspartate (RGD); metastasis; treatment resistance integrin αv; β1; β3; β6; arginine-glycine-aspartate (RGD); metastasis; treatment resistance
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Ahmedah, H.T.; Patterson, L.H.; Shnyder, S.D.; Sheldrake, H.M. RGD-Binding Integrins in Head and Neck Cancers. Cancers 2017, 9, 56.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top